M&As this week: Strides Shasun and Shanghai Fosun Pharma
Strides Shasun has announced plans to sell Shasun Pharma to its current management, a provider of contract research and manufacturing services in the UK.
Strides Shasun has announced plans to sell Shasun Pharma to its current management, a provider of contract research and manufacturing services in the UK.
The sale consideration is expected to be approximately $36m and will be completed by September 2016.
Shanghai Fosun Pharma has announced a non-binding proposal to acquire Gland Pharma for a purchase consideration ranging between $1bn and $1.5bn.
The company expects that the acquisition will help develop its drug manufacturing and research and development (R&D) capacity.
Image: Shanghai Fosun Pharma expects that the acquisition will help develop its drug manufacturing and research and development (R&D) capacity. Photo: Courtesy of Shanghai Fosun Pharma.